Prosecution Insights
Last updated: November 20, 2026
Application No. 17/997,482

ENGINEERED IMMUNOGLOBULINS

Final Rejection §112
Filed
Oct 28, 2022
Priority
May 01, 2020 — provisional 63/018,694 +1 more
Examiner
NATARAJAN, MEERA
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Novartis AG
OA Round
2 (Final)
63%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
80%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allowance Rate
482 granted / 769 resolved
+2.7% vs TC avg
Strong +18% interview lift
Without
With
+17.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
47 currently pending
Career history
822
Total Applications
across all art units

Statute-Specific Performance

§101
3.5%
-36.5% vs TC avg
§103
27.4%
-12.6% vs TC avg
§102
16.3%
-23.7% vs TC avg
§112
28.5%
-11.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 769 resolved cases

Office Action

§112
DETAILED ACTION Claim amendments filed 8/18/2026 are acknowledged and entered into the record. Claims 10-12 and 14 have been previously withdrawn. Claims 1, 3-9, 13, 15-19 and 22-29 are pending and will be examined on the merits. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections Maintained - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3-9, 16-19, 22-29 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This a written description rejection. The claims are broadly drawn to an engineered, human IgG1 immunoglobulin or fragment thereof comprising a variant Fc region which is capable of binding and activates human FcαRI, capable of binding to human FcRn, and capable of binding to human FcγRs. However, the instant specification does not provide guidance on the specific amino acids that correlates to these claimed function other than the defined sequences listed in Table 51 of full length heavy chains comprising the variant Fc regions as described in the examples as well as the light chain used to generate complete antibodies. The instant specification does not provide a structure-to-function correlation for the broad scope of Fc variants encompassed by the instant claims and therefore do not show possession of the broad range of possible Fc variants. MPEP § 2163 states that the written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus. A “representative number of species” means that the species which are adequately described are representative of the entire genus. See, e.g., AbbVie Deutschland GMBH v. Janssen Biotech, 759 F.3d 1285, 111 USPQ2d 1780 (Fed. Cir. 2014). Thus, when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus to provide a "representative number” of species. The “structural features common to the members of the genus” needed for one of skill in the art to ‘visualize or recognize’ the members of the genus takes into account the state of the art at the time of the invention. “Functional” terminology may be used “when the art has established a correlation between structure and function” but “merely drawing a fence around the outer limits of a purported genus is not an adequate substitute for describing a variety of materials constituting the genus and showing one has invented a genus and not just a species.” Ariad Pharmaceuticals Inc. v. Eli Lilly & Co., 598 F3d 1336, 94 USPQ2d 1161, 1171 (Fed Cir. 2010). The prior art shows that specific amino acid substitutions within the Fc region can have varied altered effector functions. For example, Su et al. (Antibodies, 2018, 7, 20) teach IgA Fc mutations at positions C253Y/H304R in the CH3 region of IgA2 could affect antigen binding. The instant specification teaches specific amino acid mutations with defined substitutions in the Fc IgA2 region, however the broad genus of possible Fc variants encompassed by the instant claims is not adequately described. Response to Arguments Applicant's argue in the response filed 8/18/2026 that “the federal circuit has repeatedly recognized that written description of a genus may be established through disclosure of a representative number of species” and “the present application contains a substantial number of representative engineered Fc domain species spanning the full scope of the amended claims.” These arguments have been fully considered but they are not persuasive. The amended claims recite “at least one amino acid modification is a substitution that corresponds to an amino acid in” any one of parts (a) – (d) recited in instant claim 1 and comprises at least 75% identity to instant SEQ ID NO:1. The claims also recite specific functions such as “binds to and activates human FcaR1”; “capable of binding to human FcRn”; “capable of binding to human FcyRs”; “activates human FcyRs”; “binds to FcRn”; etc. The number of possible single amino acid substitutions that would be the structural requirement of amended claim 1 is exponential and encompass a very large genus. Furthermore, the instant specification does not identify the specific residues and corresponding substitutions that would retain the functions recited in the broad scope of the claims. The specific examples of engineered Fc-domain variants taught in the instant specification satisfy the written description requirements, however they do not exemplify the broad scope encompassed by the instant claims. Therefore, the rejection of record is hereby maintained. All other previous rejections are withdrawn in view of applicants amendments to the instant claims in the response filed 8/18/2026. Conclusion Claims 1, 3-9, 16-19, 22-29 are rejected. Claims 13 and 15 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MEERA NATARAJAN whose telephone number is (571)270-3058. The examiner can normally be reached M-F 9AM - 5PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JULIE WU can be reached at 571-272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Meera Natarajan/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Oct 28, 2022
Application Filed
Mar 18, 2026
Non-Final Rejection mailed — §112
Aug 18, 2026
Response Filed
Oct 26, 2026
Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778984
CHIMERIC ANTIGEN RECEPTOR FUSION PROTEIN CO-EXPRESSING IL-7 AND CCR2B, AND APPLICATION THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12774344
ANTI-CD73 ANTIBODY AND USE THEREOF
4y 0m to grant Granted Oct 27, 2026
Patent 12774329
NOVEL CYTOKINE-BASED THERAPIES AND METHODS
1y 6m to grant Granted Oct 27, 2026
Patent 12760097
CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMOR CANCERS
5y 0m to grant Granted Oct 13, 2026
Patent 12760113
ANTI-TRANSFERRIN RECEPTOR ANTIBODIES AND USES THEREOF
2y 12m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
63%
Grant Probability
80%
With Interview (+17.8%)
3y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 769 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month